The optimal therapy for children with Hodgkin 's disease is controversial. Between 1989 and 1993, 53 children under 14 years of age with Hodgkin's disease were treated with COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin, vinblastine) hybrid chemotherapy. The results were analyzed with the Kaplan-Meier product limit method for survival and the Logrank test for predicting statistical significance. Ten patients (18.87% had early-stage disease (I to IIA) and 43 (81.13% had advanced disease. Lymphocyte-predominant histology was seen in 20 (37.5% patients, nodular sclerosis in 8 (15% mixed cellularity in 21 (39.6% and lymphocyte depletion in 4 (7.56% The male: female ratio was 3.82:1. Complete responses were seen in 51 (96.22% patients, with 47 (92.15% of them in sustained first remission. The event-free survival rate is 90.3% to date. COPP/ABV hybrid chemotherapy is an effective primary therapy for all stages of Hodgkin's disease in children.
- Childhood Hodgkin's disease
- Hybrid chemotherapy